Hims & Hers Health stock dropped 5% after reporting revenue below analyst estimates, though earnings per share beat expectations. The company’s full-year revenue guidance remains steady at $2.3 billion-$2.4 billion. Novo Nordisk ended a partnership with Hims due to concerns over illegal mass compounding and deceptive marketing. Shares in Novo Nordisk fell over 21% after cutting profit forecasts for Wegovy and Ozempic. The FDA allowed compounding pharmacies to copy and distribute weight-loss drugs, benefiting Hims temporarily. Hims is expanding its product offerings after the FDA’s order ended in February. Despite recent challenges, Hims’ stock has risen over 150% this year, outperforming Novo and Eli Lilly. CEO Andrew Dudum remains optimistic about the company’s future success.

Read more at Yahoo Finance: Hims & Hers stock slides 5% after second quarter revenue misses forecasts